Search results for "TYPE 2 DIABETES MELLITUS"

showing 10 items of 198 documents

Effect of insulin on readmission for heart failure following a hospitalization for acute heart failure

2020

AIMS: Type 2 diabetes mellitus (T2DM) is common in patients with heart failure (HF) and is related with worse outcomes. Insulin treatment is associated with sodium and water retention, weight gain, and hypoglycaemia-all pathophysiological mechanisms related to HF decompensation. This study aimed to evaluate the association between insulin treatment and the risk of 1year readmission for HF in patients discharged for acute HF.; METHODS AND RESULTS: We prospectively included 2895 consecutive patients discharged after an episode of acute HF in a single tertiary hospital. Multivariable Cox regression, adapted for competing events, was used to assess the association between insulin treatment and …

medicine.medical_specialtymedicine.medical_treatment030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineInternal medicineDiabetes mellitusOriginal Research ArticlesType 2 diabetes mellitusmedicineDiseases of the circulatory (Cardiovascular) systemDecompensation030212 general & internal medicineOriginal Research ArticleEjection fractionbusiness.industryProportional hazards modelInsulinHazard ratioType 2 Diabetes MellitusAcute heart failureHospital readmissionmedicine.diseaseHeart failureRC666-701Insulin therapyCardiology and Cardiovascular Medicinebusiness
researchProduct

Translating results from the cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists into clinical practice: Recommendations fr…

2022

Glucagon-like peptide-1 (GLP-1) receptor agonists mimic the action of the endogenous GLP-1 incretin hormone, improving glycaemic control in type 2 diabetes mellitus (T2DM) by increasing insulin secretion and decreasing glucagon secretion in a glucose-dependent manner. However, as cardiovascular (CV) morbidity and mortality is common in patients with T2DM, several trials with the use of GLP-1 receptor agonists (RAs) have been performed focusing on endpoints related to cardiovascular disease rather than metabolic control of T2DM. Following the positive cardiovascular effects of liraglutide, dulaglutide and semaglutide observed in these trials, major changes in T2DM management guidelines have …

Diabetes Mellitus Type 2Cardiovascular DiseasesGlucagon-Like Peptide 1HumansHypoglycemic AgentsAlgorithm Cardiovascular outcomes trials GLP-1 receptor agonists Treatment Type 2 diabetes mellitusLiraglutideCardiology and Cardiovascular MedicineAlgorithm ; Cardiovascular outcomes trials ; GLP-1 receptor agonists ; Treatment ; Type 2 diabetes mellitus.Glucagon-Like Peptide-1 ReceptorInternational Journal of Cardiology
researchProduct

Anti-inflammatory Therapies for Cardiovascular Disease: Signaling Pathways and Mechanisms

2019

Cardiovascular diseases (CVD) are the clinical manifestation of atherosclerosis, a chronic inflammatory disease promoted by several risk factors such as dyslipidemia, type 2 diabetes mellitus, hypertension, and smoking. Acute CVD events are the result of an unresolved inflammatory chronic state that promotes the rupture of unstable plaque lesions. Of note, the existing intensive therapies modify risk factors but do not prevent life-threatening recurrent ischemic events in high-risk patients, who have a residual inflammatory risk displayed by increased C-reactive protein (CRP) levels. Better understanding of the role of innate and adaptive immunity in plaque development and rupture has led t…

Inflammationbusiness.industrymedicine.medical_treatmentAnti-Inflammatory AgentsType 2 Diabetes MellitusGeneral MedicineDisease030204 cardiovascular system & hematologymedicine.diseaseBioinformaticsAcquired immune systemClinical trial03 medical and health sciencesC-Reactive Protein0302 clinical medicineCytokineCardiovascular DiseasesPsoriasisRheumatoid arthritismedicineHumansbusinessBiomarkersDyslipidemiaSignal TransductionRevista Española de Cardiología (English Edition)
researchProduct

A Systematic Study of Dysregulated MicroRNA in Type 2 Diabetes Mellitus

2017

MicroRNAs (miRNAs) are small noncoding RNAs that modulate the cellular transcriptome at the post-transcriptional level. miRNA plays important roles in different disease manifestation, including type 2 diabetes mellitus (T2DM). Many studies have characterized the changes of miRNAs in T2DM, a complex systematic disease; however, few studies have integrated these findings and explored the functional effects of the dysregulated miRNAs identified. To investigate the involvement of miRNAs in T2DM, we obtained and analyzed all relevant studies published prior to 18 October 2016 from various literature databases. From 59 independent studies that met the inclusion criteria, we identified 158 dysregu…

0301 basic medicineSystematic surveytype 2 diabetes mellitussystematic study030209 endocrinology & metabolismDiseaseBioinformaticsCatalysisArticleInorganic ChemistryTranscriptomelcsh:Chemistry03 medical and health sciences0302 clinical medicineDiabetes mellitusmiRNA-mRNA interaction networkmicroRNAmedicineHumansGene Regulatory NetworksRNA MessengerPhysical and Theoretical Chemistry10. No inequalityMolecular Biologylcsh:QH301-705.5SpectroscopyAdipocytokine Signaling PathwaymicroRNA; type 2 diabetes mellitus; miRNA-mRNA interaction network; systematic studymicroRNAbusiness.industryGene Expression ProfilingOrganic ChemistryType 2 Diabetes MellitusGeneral Medicinemedicine.diseaseComputer Science ApplicationsMicroRNAs030104 developmental biologyDiabetes Mellitus Type 2Gene Expression Regulationlcsh:Biology (General)lcsh:QD1-999Organ SpecificityRNA InterferenceDisease manifestationbusinessTranscriptomeSignal TransductionInternational Journal of Molecular Sciences
researchProduct

GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms

2018

Type 2 diabetes mellitus (T2DM) is a metabolic condition with an elevated impact on cardiovascular (CV) risk. The innovative therapeutic approaches for T2DM - incretin-based therapies (IBTs), including glucagon-like peptide 1 (GLP-1) receptor agonists, have become popular and more widely used in recent years. The available scientific data from clinical studies and clinical practice highlights their beyond glucose-lowering effects, which is achieved without any increase in hypoglycaemia. The former effects include reduction in body weight, lipids, blood pressure, inflammatory markers, oxidative stress, endothelial dysfunction, and subclinical atherosclerosis, thus reducing and potentially pr…

Blood GlucoseCardiometabolic parameterGlucagon-Like PeptidesIncretin030209 endocrinology & metabolism030204 cardiovascular system & hematologyBioinformaticsIncretinsGlucagon-Like Peptide-1 Receptor03 medical and health sciences0302 clinical medicineDiabetes mellitusmedicineHumansHypoglycemic AgentsEndothelial dysfunctionMolecular BiologyGlucagon-like peptide 1 receptorLiraglutidebusiness.industryType 2 Diabetes MellitusLiraglutideCardiovascular riskmedicine.diseasePlaque AtheroscleroticType 2 diabetes mellituBlood pressureDiabetes Mellitus Type 2Cardiovascular DiseasesMetabolic control analysisGlucagon-like peptide 1 receptor agonistMolecular Medicinebusinessmedicine.drugBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
researchProduct

Genetic susceptibility of increased intestinal permeability is associated with progressive liver disease and diabetes in patients with non-alcoholic …

2020

Abstract Background and aim Increased intestinal permeability plays a key role in the pathogenesis of fat deposition in the liver. The aim of our study was to assess whether a single nucleotide polymorphism of protein tyrosine phosphatase non-receptor type 2 (PTPN2) (rs2542151 T→G), involved in intestinal permeability, may be associated with non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM). Methods and results We recruited a prospective cohort of NAFLD subjects and matched controls. Clinical data, PTPN2 genotype and laboratory data were collected for each patient. Results were stratified according to liver histology and diabetes. We enrolled 566 cases and 377 co…

Liver CirrhosisMaleEndocrinology Diabetes and MetabolismMedicine (miscellaneous)030204 cardiovascular system & hematologySeverity of Illness IndexGastroenterologyLiver disease0302 clinical medicineNon-alcoholic Fatty Liver DiseaseRisk FactorsNonalcoholic fatty liver diseasePrevalenceProspective StudiesProtein Tyrosine Phosphatase Non-Receptor Type 2Nutrition and Dieteticsmedicine.diagnostic_testFatty liverMiddle AgedPhenotypeItalyLiver biopsyFemaleCardiology and Cardiovascular MedicineAdultmedicine.medical_specialtySettore MED/12 - GASTROENTEROLOGIA030209 endocrinology & metabolismIntestinal permeabilityPolymorphism Single NucleotideRisk AssessmentPermeability03 medical and health sciencesInternal medicineDiabetes mellitusmedicineGenetic susceptibilityHumansNonalcoholic fatty liver diseaseGenetic Predisposition to DiseaseGenetic Association Studiesbusiness.industryType 2 Diabetes Mellitusmedicine.diseaseCross-Sectional StudiesDiabetes Mellitus Type 2Intestinal AbsorptionCase-Control StudiesSteatosisSteatohepatitisbusiness
researchProduct

A Decision Support Tool for Appropriate Glucose-Lowering Therapy in Patients with Type 2 Diabetes

2015

Contains fulltext : 152084.pdf (Publisher’s version ) (Open Access) BACKGROUND: Optimal glucose-lowering therapy in type 2 diabetes mellitus requires a patient-specific approach. Although a good framework, current guidelines are insufficiently detailed to address the different phenotypes and individual needs of patients seen in daily practice. We developed a patient-specific decision support tool based on a systematic analysis of expert opinion. MATERIALS AND METHODS: Based on the American Diabetes Association (ADA)/European Association for the Study of Diabetes (EASD) 2012 position statement, a panel of 12 European experts rated the appropriateness (RAND/UCLA Appropriateness Method) of tre…

medicine.medical_specialtyDecision support systemEndocrinology Diabetes and Metabolism[SDV]Life Sciences [q-bio]MEDLINEType 2 diabetesComorbidityHypoglycemiaGlucagon-Like Peptide-1 ReceptorBody Mass IndexEndocrinologyLife ExpectancyClinical ProtocolsInternal medicineHealth careReceptors GlucagonMedicineHumansHypoglycemic AgentsInsulinPrecision MedicineIntensive care medicineExpert TestimonyReimbursementComputingMilieux_MISCELLANEOUSGlycated HemoglobinDipeptidyl-Peptidase IV InhibitorsPioglitazonebusiness.industryDrug SubstitutionType 2 Diabetes MellitusMetabolic Disorders Radboud Institute for Molecular Life Sciences [Radboudumc 6]Original ArticlesPrecision medicinemedicine.diseaseDecision Support Systems ClinicalHypoglycemiaMetformin3. Good healthEuropeMedical Laboratory TechnologyEndocrinologySulfonylurea CompoundsDiabetes Mellitus Type 2Drug Therapy CombinationThiazolidinedionesbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

The importance of diagnosing the Polycystic Ovary Syndrome

2000

The polycystic ovary syndrome (PCOS) is an extremely common disorder that occurs in 4% to 7% of women of reproductive age. Although PCOS is known to be associated with reproductive morbidity and increased risk for endometrial cancer, diagnosis is especially important because PCOS is now thought to increase metabolic and cardiovascular risks. These risks are strongly linked to insulin resistance and are compounded by the common occurrence of obesity, although insulin resistance and its associated risks are also present in nonobese women with PCOS. Women with PCOS are at increased risk for impaired glucose tolerance, type 2 diabetes mellitus, and hypertension. Cardiovascular disease is believ…

medicine.medical_specialtyendocrine system diseasesPhysiologyType 2 diabetesImpaired glucose toleranceInsulin resistanceDiabetes mellitusInternal medicineGlucose IntoleranceInternal MedicinemedicineHumansRisk factorbusiness.industryFibrinolysisnutritional and metabolic diseasesType 2 Diabetes MellitusGeneral Medicinemedicine.diseaseObesityPolycystic ovaryLipidsfemale genital diseases and pregnancy complicationsEndocrinologyCardiovascular DiseasesFemalepolycystic ovary syndrome cardiovascular risk insuline resistanceInsulin ResistancebusinessHyperandrogenismAnovulationPolycystic Ovary Syndrome
researchProduct

Analysis of the Impact of Disease Acceptance, Demographic, and Clinical Variables on Adherence to Treatment Recommendations in Elderly Type 2 Diabete…

2021

This project aimed to analyze the impact of disease acceptance and selected demographic and clinical factors on the adherence to treatment recommendations in elderly type 2 diabetes mellitus patients. The observational study was performed using standardized research questionnaires: the Acceptance of Illness Scale (AIS), the Self-Care of Diabetes Inventory (SCODI), and the Adherence in Chronic Diseases Scale (ACDS). Two hundred patients with T2DM were studied (age M = 70.21 years, SD = 6.63 years). The median degree of disease acceptance was 29 (min–max = 8–40) and the median level of adherence was 24 (min–max = 13–28). Disease acceptance was a significant (p = 0.002) independent predictor o…

Biopsychosocial modelmedicine.medical_specialtytype 2 diabetes mellitusHealth Toxicology and MutagenesisPsychological interventionDiseasecomplianceArticleMedication AdherenceSurveys and QuestionnairesDiabetes mellitusInternal medicineHumansMedicineadherenceDemographyGlycemicbusiness.industryPublic Health Environmental and Occupational HealthRType 2 Diabetes Mellitusmedicine.diseaseSelf CareagedDiabetes Mellitus Type 2PillMedicineObservational studybusinessInternational Journal of Environmental Research and Public Health
researchProduct

Type 2 diabetes mellitus and osteoarthritis

2019

Objectives: Type 2 diabetes mellitus (T2DM) and osteoarthritis (OA) are common diseases that frequently co-exist, along with overweight/obesity. While the mechanical impact of excess body weight on joints may explain lower limb OA, we sought to explore whether T2DM is linked to OA outside of excess weight and whether T2DM may play a role in OA pathophysiology. The consequence of T2DM on OA outcomes is a question of research interest. Methods: We conducted a critical review of the literature to explore the association between T2DM and OA, whether any association is site-specific for OA, and whether the presence of T2DM impacts on OA outcomes. We also reviewed the literature to assess the saf…

medicine.medical_specialtyEvidence-based practicetype 2 diabetes mellituendocrine system diseasesMedicinaOsteoarthritisOverweightPathophysiologyArticle03 medical and health sciences0302 clinical medicineInsulin resistanceRheumatologyInternal medicineOsteoarthritisType 2 diabetes mellitusMedicineHumans030212 general & internal medicineObesityRisk factor030203 arthritis & rheumatologyddc:616[SDV.MHEP.EM] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism[SDV.MHEP.RSOA] Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal systembusiness.industryType 2 Diabetes Mellitusnutritional and metabolic diseases[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolismmedicine.diseaseObesity3. Good healthInstitutional repositoryAnesthesiology and Pain MedicineDiabetes Mellitus Type 2[SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal systemDisease Progressionosteoarthritimedicine.symptomInsulin ResistanceSafetybusiness
researchProduct